Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

MLA

de Vries, J. J. C., et al. “Incorporation of LpxL1, a Detoxified Lipopolysaccharide Adjuvant, in Influenza H5N1 Virosomes Increases Vaccine Immunogenicity.” Vaccine, vol. 27, no. 6, Feb. 2009, pp. 947–55. EBSCOhost, https://doi.org/10.1016/j.vaccine.2008.11.046.

APA

de Vries, J. J. C., Bungener, L., Ter Veer, W., van Alphen, L., van der Ley, P., Wilschut, J., & Huckriede, A. (2009). Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine, 27(6), 947–955. https://doi.org/10.1016/j.vaccine.2008.11.046

Chicago

de Vries, J J C, L Bungener, W Ter Veer, L van Alphen, P van der Ley, J Wilschut, and A Huckriede. 2009. “Incorporation of LpxL1, a Detoxified Lipopolysaccharide Adjuvant, in Influenza H5N1 Virosomes Increases Vaccine Immunogenicity.” Vaccine 27 (6): 947–55. doi:10.1016/j.vaccine.2008.11.046.